Objective: To understand the prevalence of H.pylori infection in patients with cirrhosis, and liver cirrhosis with hepatocellular carcinoma(HCC), and to investigate the relationship between H.pylori infection and liver cirrhosis, and liver cirrhosis with hepatocellular carcinoma in patients.
Methods: Serum anti-H.pylori antibodies IgG (HpIgG) was measured by dot immunogold filtration assay (DIGFA) in 101 liver cirrhosis and 42 liver cirrhosis with hepatoma patients and alpha-fetopro-tei(AFP)was determined by chemiluminescence.
Results: HpIgG seroprevalence was 42.57% (43/101) in the liver cirrhosis patients, and 69.05% (29/42) in the liver cirrhosis with the HCC patients. HpIgG seropositivity in the liver cirrhosis with the HCC patients was higher than in those without HCC. HpIgG seropositivity in the HBV positive patients was higher than in the HBV negative patients (chi2=4.164, P=0.041). HpIgG seropositivity in the AFP abnormal patients was higher than in the AFP normal patients (chi2=4.695, P=0.030).
Conclusion: H.pylori may be a risk factor in patients with cirrhosis and HCC.